REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 2nd, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 2nd, 2003 Company Industry JurisdictionThis Registration Rights Agreement (this "Agreement") is made and entered into as of July 1, 2003, by and among AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and the investors signatory hereto (each a "Purchaser" and collectively, the "Purchasers").
COMMON STOCK PURCHASE WARRANT To Purchase 444,444 Shares of Common Stock of AVANT Immunotherapeutics, Inc.Securities Agreement • July 2nd, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances
Contract Type FiledJuly 2nd, 2003 Company IndustryTHIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, The Riverview Group, LLC (the "Holder"), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after July 1, 2003 (the "Initial Exercise Date") and on or prior to the close of business on June 30, 2008 (the "Termination Date") but not thereafter, to subscribe for and purchase from AVANT Immunotherapeutics, Inc., a corporation incorporated in the State of Delaware (the "Company"), up to 444,444 shares (the "Warrant Shares") of Common Stock, par value $0.001 per share, of the Company (the "Common Stock"). The purchase price of one share of Common Stock (the "Exercise Price") under this Warrant shall be $3.00, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. Capitalized terms used and not otherwise defined herein shall ha
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2003 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New York
Contract Type FiledJuly 2nd, 2003 Company Industry JurisdictionThis Securities Purchase Agreement (this "Agreement") is dated as of July 1, 2003, among AVANT Immunotherapeutics, Inc., a Delaware corporation (the "Company"), and the purchasers identified on the signature pages hereto (each a "Purchaser" and collectively the "Purchasers"); and